Abstract:Histone deacetylase inhibitors (HDACi) such as trichostatin A (TSA) and Sodium Butyrate (NaB) can regulate gene expression by acetylating histones and transcription factors. HDACi attenuate expression of certain NF-kB-regulated cytokines, including TNF-α, IL-1β, IL-6, and IFN-γ in some inflammatory disease models. Human tissue fatctor (TF) expression is, in part, governed by a unique, NF-kB-related “TF-kB” promoter binding site. We hypothesized that HDACi would inhibit induction of TF expression by physiologic agonists. We assessed the effect of TSA and NaB upon TF expression in human umbilical vein endothelial cells (HUVEC) and peripheral blood mononuclear cells (PBM) in response to 1 ng/ml TNF-α, 1 ng/ml IL-1β, 1 μg/ml LPS, and 100 μM HOSCN, a potent phagocyte peroxidase-derived oxidant. HUVEC monlayers and PBM were pretreated with TSA (0.01–1 μM) or NaB (1–10 mM) for 4 h prior to agonist addition and 4 h later whole cell lysates were assayed for TF activity by 1-stage clotting assay and western blots probed for TF. Both TSA and NaB inhibit HUVEC TF activity and protein expression up to 90% with respective IC50's of 30–50 nM and 2 mM. TSA decreases PBM TF activity induced by LPS and IL-1β by 50–65% with similar potency. In striking contrast, western blots show no effect of TSA on agonist-induced expression of the NF-kB-regulated adhesion molecules ICAM-1 and E-selectin. RT-PCR analysis shows TNF-α stimulation induces a 22-fold increase of TF mRNA that is attenuated up to 70% by TSA treatment without affecting the 10-fold ICAM-1 mRNA increase. TSA did not influence TF translational efficiency as detected by polyribosomal TF mRNA distribution and TSA TF inhibition was unaffected by the ubiquitin-dependent protein degradation inhibitor MG-132. EMSA analysis of HUVEC nuclear extracts using probes for the SP1, AP-1, Egr-1 and TF-kB transcription factor binding sites in the TF gene promoter shows that SP1, AP-1 and Egr-1 are constitutively activated in HUVEC and are unaffected by LPS or TNF-α irrespective of whether TSA is present. However, both TNF-α and LPS induce abundant p65/p50 and p65/c-Rel heterodimer binding to both the NF-kB and TF-kB probes. 0.3 μM TSA nearly completely abolishes TF-kB activation without affecting NF-kB activation. TSA has no effect on TNF-α-induced cytoplasmic IkB-α degradation or nuclear translocation of c-Rel, p65, or p50. Chromatin immunoprecipitation assay shows that TSA strongly inhibits p65 binding to the authentic endogenous HUVEC TF-kB site in the TF promoter induced by TNF-α without affecting p65 binding to the ICAM-1 NF-kB site. A HUVEC promoter-luciferase reporter system confirms the complete specificity of TSA's inhibitory effect on LPS- or TNF-α- induced TF expression for TF-kB rather than NF-kB. We conclude that HDACi transcriptionally inhibit agonist-induced TF expression in human endothelial cells and monocytes by specific blockade of TF-kB activation. We propose that histone deacetylases play a previously unsuspected role in regulating TF expression and HDACi might be a novel therapy for thrombotic diseases.

A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture

Trichostatin A Inhibits the Activation of Hepatic Stellate Cells by Increasing C/EBP-α Acetylation in Vivo and in Vitro.

Effects of trichostatin A on the expressions of inflammatory cytokines and toll-like receptor 4 and the acetylation of nuclear factor-κB induced by lipopolysaccharide in macrophage

Histone deacetylase inhibition suppresses the transforming growth factor β1–induced epithelial‐to‐mesenchymal transition in hepatocytes

Liver Fibrosis Therapy Based on Biomimetic Nanoparticles Which Deplete Activated Hepatic Stellate Cells.

Targeting Transforming Growth Factor Βrii Expression Inhibits the Activation of Hepatic Stellate Cells and Reduces Collagen Synthesis

Trichostatin A Protects Against Intestinal Injury in Rats with Acute Liver Failure.

Effects of all-trans retinioc acid on expressions of COL1α2,MMP-2,TIMP-1, and signaling pathway in TGF-β1-simulated rat hepatic stellate cells

Trichostatin A Inhibits Inflammation in Phorbol Myristate Acetate-Induced Macrophages by Regulating the Acetylation of Histone And/Or Non-Histone Proteins

Trichostatin A inhibits collagen synthesis and induces apoptosis in keloid fibroblasts

Effects of Histone Deacetylase Inhibitor Trichostatin A on Proliferation and Adipogenic Differentiation of C3H10T1/2 Mesenchymal Stem Cells

Trichostatin A regulates fibro/adipogenic progenitor adipogenesis epigenetically and reduces rotator cuff muscle fatty infiltration

TSA Increases C/EBP-α Expression by Increasing Its Lysine Acetylation in Hepatic Stellate Cells

Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.

“Tf-Kb”-dependent Suppression of Agonist-Mediated Tissue Factor Induction by Histone Deacetylase Inhibitors in Human Endothelial Cells and Monocytes.

Trichostatin A Increases the TIMP-1/MMP Ratio to Protect Against Osteoarthritis in an Animal Model of the Disease.

Trichostatin A Protects Against Experimental Acute-on-Chronic Liver Failure in Rats Through Regulating the Acetylation of Nuclear Factor-κB

Effect of Trichostatin A (TSA) on Histone Acetylation and Methylation in Bovine Fibroblast Cells

Alleviation of Osteoarthritis by Trichostatin A, a Histone Deacetylase Inhibitor, in Experimental Osteoarthritis

Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells

Prevention of Pulmonary Fibrosis Via Trichostatin A (tsa) in Bleomycin Induced Rats